within Pharmacolibrary.Drugs.ATC.M;

model M01BA03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 0.25,
    adminDuration  = 600,
    adminMass      = 0.5,
    adminCount     = 1,
    Vd             = 0.01,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.004166666666666667,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Acetylsalicylic acid (aspirin) and corticosteroids is a fixed drug combination classified under ATC code M01BA03, primarily used for its anti-inflammatory, analgesic, and antipyretic effects. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) and corticosteroids suppress immune response and inflammation. Such combinations have been used in various inflammatory conditions such as rheumatoid arthritis. Fixed combinations of aspirin and corticosteroids are rarely used in current clinical practice due to the risk of gastrointestinal toxicity and more effective therapies being available.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for an average healthy adult following oral administration, based on known PK of acetylsalicylic acid and common corticosteroids (such as prednisolone); no direct publication with population PK modeling data for the fixed combination.</p><h4>References</h4><ol><li><p>Miners, JO (1989). Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid. <i>Clinical pharmacokinetics</i> 17(5) 327–344. DOI:<a href=&quot;https://doi.org/10.2165/00003088-198917050-00003&quot;>10.2165/00003088-198917050-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2573442/&quot;>https://pubmed.ncbi.nlm.nih.gov/2573442</a></p></li><li><p>Verbeeck, RK (1990). Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs. <i>Clinical pharmacokinetics</i> 19(1) 44–66. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199019010-00004&quot;>10.2165/00003088-199019010-00004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2199127/&quot;>https://pubmed.ncbi.nlm.nih.gov/2199127</a></p></li><li><p>Dekhuijzen, PN, &amp; Koopmans, PP (2002). Pharmacokinetic profile of zafirlukast. <i>Clinical pharmacokinetics</i> 41(2) 105–114. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200241020-00003&quot;>10.2165/00003088-200241020-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11888331/&quot;>https://pubmed.ncbi.nlm.nih.gov/11888331</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end M01BA03;
